Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunologic specificity of transfer factor.

K S Zuckerman, J A Neidhart, S P Balcerzak

    The Journal of Clinical Investigation
    |October 1, 1974
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Role of cell cycle regulatory molecules in retinoic acid- and vitamin D3-induced differentiation of acute myeloid leukaemia cells.

    Cell proliferation·2014
    Same author

    TGFbeta inhibits GM-CSF-induced phosphorylation of ERK and MEK in human myeloid leukaemia cell lines via inhibition of phosphatidylinositol 3-kinase (PI3-k).

    Cell proliferation·2009
    Same author

    Phase II Trial of Dolastatin-10, a Novel Anti-Tubulin Agent, in Metastatic Soft Tissue Sarcomas.

    Sarcoma·2008
    Same author

    Differential effects of transforming growth factor on cell cycle regulatory molecules in human myeloid leukemia cells.

    Oncogene·2001
    Same author

    Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study.

    Cancer biotherapy & radiopharmaceuticals·2001
    Same author

    An IkappaBalpha inhibitor causes leukemia cell death through a p38 MAP kinase-dependent, NF-kappaB-independent mechanism.

    Cancer research·2001
    Same journal

    Julie Zikherman receives the ASCI/Marian W. Ropes, MD, Award.

    The Journal of clinical investigation·2026
    Same journal

    Targeted degradation of MDM2 overcomes feedback regulation of p53 signaling in Merkel cell carcinoma models.

    The Journal of clinical investigation·2026
    Same journal

    SGLT2 inhibitors enhance ketogenesis by acting as allosteric activators of the mitochondrial enzyme HMGCS2.

    The Journal of clinical investigation·2026
    Same journal

    MDM2 degraders for Merkel cell carcinoma: round peg in a round hole.

    The Journal of clinical investigation·2026
    Same journal

    Ammonia in the crosshairs: microbial targets for metabolic dysfunction-associated steatohepatitis prevention.

    The Journal of clinical investigation·2026
    Same journal

    Molecular mechanisms regulating cGAS/STING activation in health and disease.

    The Journal of clinical investigation·2026
    See all related articles

    Transfer factor, a substance that transfers immunity, demonstrated specific immune responses in recipients. This purified transfer factor successfully transferred immunity to keyhole limpet hemocyanin (KLH) and showed potential for clinical applications.

    Area of Science:

    • Immunology
    • Cellular immunology

    Background:

    • Transfer factor is a cell-free substance that can transfer delayed-type hypersensitivity.
    • Its immunologic specificity has been a subject of ongoing research.

    Purpose of the Study:

    • To examine the immunologic specificity of a chromatographically purified transfer factor preparation.
    • To assess the ability of transfer factor to induce specific immune responses in recipients.

    Main Methods:

    • Utilized a purified transfer factor preparation derived from donors with known immunity.
    • Tested specificity using keyhole limpet hemocyanin (KLH) and tuberculin as antigens.
    • Assessed immune transfer via skin test reactivity in recipients.

    Main Results:

    Related Experiment Videos

  • Transfer factor from KLH-immune donors successfully transferred KLH skin test reactivity to all recipients (10/10).
  • Transfer factor from non-immune donors failed to transfer KLH immunity but successfully transferred tuberculin reactivity.
  • Induced KLH immunity in recipients was comparable to donor immunity, elicitable with the same antigen dose.

    • Conclusions:

    • Transfer factor can initiate a specific immune response to a novel antigen in recipients.
    • The induced immune response can be as potent as the donor's response.
    • Findings have significant implications for the clinical use of transfer factor.